Is ADMA Biologics, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for ADMA Biologics, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 24, a Price to Book Value of 13.18, and an EV to EBITDA of 30.78, which suggest a balanced valuation relative to its earnings and assets.
In comparison to its peers, ADMA Biologics, Inc. has a P/E ratio of 18.56, while Protagonist Therapeutics, Inc. is considered very expensive with a P/E of 67.18. This indicates that ADMA is positioned more favorably in terms of valuation compared to some competitors. Notably, while ADMA's stock has underperformed against the S&P 500 in the short term, with a year-to-date return of -16.27% compared to the S&P 500's 13.30%, it has significantly outperformed over longer periods, with a 3-year return of 433.83% versus 81.19% for the index.